Anthropic's Claude Accelerates Drug Development Across Six Partnerships

October 28, 2026

Anthropic's life sciences team has published early results from deep research partnerships with six organizations using Claude to accelerate drug development. The work spans the entire drug development pipeline, from identifying targets to drafting regulatory filings, and includes drug discovery efforts run by Anthropic itself.[1]

The partnerships cover distinct stages of drug development. Generate Biomedicines worked with Claude Code to redesign part of a CAR T-cell therapy, aiming to extend it from blood cancers to solid tumors. One Claude-proposed design was 70% shorter than the standard version and, in lab tests, allowed immune cells to produce roughly 10 times as many cancer-detecting receptors while killing tumor cells more efficiently.[1]

Divergence Labs used Claude to generate approximately 35'000 antibody designs in about a month for a novel food allergy treatment. The approach targets detaching IgE from immune cells entirely, rather than just neutralizing circulating IgE as standard medications do. Early tests found hits for both arms of the required design, with three candidates outperforming the standard medication in dislodging IgE.[1]

BigHat Biosciences paired Claude with its automated lab to optimize two drug leads. Over 10 weeks, the system made and tested about 1'010 variants. The best versions bound more than 10 times more tightly to their targets, with one lead showing 18°C improved heat stability and another clumping more than 100 times more slowly than the originals. Midway through, Claude helped reanalyze raw data and proposed different stability metrics, which held up under testing.[1]

Enveda focused on manufacturing and regulatory paperwork, where chemists previously spent up to 75% of their time on documentation. A system connecting manufacturing documents to Claude caught all 11 issues that human reviewers had identified across 1'061 pages, plus seven they had missed. Review time dropped by 89%, from over 25 hours to under three. Claude also drafted two regulatory documents, one in four hours compared to the usual three months by hand.[1]

The Column Group is establishing a new company, Pleiades, built around using Claude to run more drug programs with a small team. Its first Claude skill, for assessing whether drug targets are worth pursuing, has been evaluated on 45 target-disease pairs. Bristol Myers Squibb is using Claude to assess clinical trial plans and estimate success probabilities.[1]

Anthropic has also acquired Mithril Medicine, a one-person company developing treatments for rare childhood muscular dystrophies. Its founder used Claude to manage contracts, logistics, and experiments with 11 external labs, taking a treatment from idea to promising mouse results in under 18 months. If candidates continue to hold up, human clinical trials could begin as early as late 2028.[1]

All research is still at an early, mostly preclinical stage. Anthropic plans to expand into clinical trials as programs advance, and has launched Claude Science, a workbench for researchers, along with a Life Sciences Verification Program for trusted organizations to use more powerful models with relaxed safeguards for legitimate biological research.[1]

Sources:

[1] Anthropic, "Early progress on accelerating drug development with Claude," October 2026